US Senate Committee on Finance 01/31/2019

Dr. Bach Testifies at U.S. Senate Committee on Finance's First Hearing of Session

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

On Tuesday, January 29, 2019, Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I. The hearing, led by Senator Chuck Grassley (R-IA), chairman of the Finance Committee, took place in accordance with released statement naming health care costs as “top priority“. During his testimony, Dr. Bach presented an overview of the pharmaceutical supply chain and evidence-based policy options, many of which are supported by Drug Pricing Lab research. These policy options include a subscription model for HCV treatment, reforms to Medicare Part B and Part D, such as modifying the ASP+6% reimbursement to a flat fee, improved competition for high priced therapies like CAR-T therapies by way of various entities’ authority over coverage decisions and alternative payment testing, value-based pricing, and implementation of an international pricing index.

Read full written testimony here.

 

Share

Research & Insights

We conduct non-partisan, independent research, and make our work accessible and informative to policymakers and the general audience alike. Browse our featured research or explore our work by article type.

Pharmaceutical Products and Their Value
Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.
Value in Health 03/29/2020
Value-Based Pricing for Drugs: Theme and Variations
A taxonomy of the features that make a payment model truly value-based.
JAMA Viewpoint 05/02/2018
Production Plus Profit Pricing (P-quad) FAQ
08/17/2021
What A Waste! The National Academy Of Medicine’s Report On…
Why Congress should not follow the National Academy of Science, Engineering, and Medicine’s recommendation to remove the JW modifier.
Health Affairs Blog 07/09/2021
Medicare Must Study Unproven, Expensive Alzheimer’s Drug
Medicare cannot indiscriminately cover the cost of Aduhelm for the treatment of Alzheimer's disease without first evaluating whether it truly works.
Bloomberg Opinion 06/15/2021
Value-Based Management of Specialty Drugs: Practical Considerations and Implications for…
Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.
AJMC 05/13/2021
The Drugs at the Heart of Our Pricing Crisis
The US drug pricing system is broken, but not irreparable. For large-molecule biologic drugs, enter: Production Plus Profit Pricing (P-quad, pronounced like Ahab's seagoing vessel).
NYTimes 03/15/2021
Biosimilars: Market Changes do not equal policy success
Numerous articles and reports have trumpeted biosimilar market growth, but it's critical we do not lose sight of the sole objective for creating the biosimilar market: to reduce the cost of older biologic drugs for society and taxpayers.
Drug Pricing Lab 03/15/2021
Instead of debating 'first-shot' vs 'set-aside' vaccine approaches, hospitals' study…
Hospitals could start studies of their own employees to answer important questions, including whether the first-shot approach has downsides when compared to the set-aside strategy.
STAT 01/04/2021
After 4 Years of Trump, Medicare and Medicaid Badly Need…
Many promising ideas won't work as expected, and that's all the more reason for CMS to evaluate how medical care is delivered to its patients.
NYTimes 12/01/2020
Trump's Drug-Pricing Ideas Would Cost Taxpayers a Bundle
Meanwhile, pharmaceutical companies would stand to make a lot more money.
Bloomberg Opinion 09/29/2020
We can't tackle the pandemic without figuring out which Covid-19…
There may be several Covid-19 vaccines by winter, but there will also need to be a study comparing the viruses to one another as part of rolling out widespread vaccination.
STAT 09/24/2020
Newsletter

Stay up to date on our work and news